Log in
Research undertaken by Professor Woodroofe has impacted on a range of beneficiaries: people with multiple sclerosis (MS), their families and carers, and health professionals, including nurses, physiotherapists and doctors. This has been achieved through an array of innovative dissemination activities involving shared learning among researchers and beneficiaries. Through these activities beneficiaries gained a greater knowledge and deeper understanding of the disease process in MS, which they subsequently shared within their own networks. Woodroofe's research on MS has been published in leading international journals making an important contribution to the field and underpinning the impact achieved.
Q-Technologies Limited is an award winning company spun out from the University of Liverpool (UoL). The company mission is to bring to market the novel, patented technology developed through research undertaken by Taylor and colleagues in the Mass Spectrometry (MS) research group in the Department of Electrical Engineering and Electronics from 1995. Impact is economic resulting from formation of a profitable business, currently employing 7 people, and via IP assignment generating £1.2M in 2013. Impact is also environmental via the realisation of a novel sensor with unparalleled monitoring capabilities providing improved water quality monitoring.
This case study summarises a body of research on Multiple Sclerosis (MS) developed at Plymouth University under the leadership of Professor Zajicek and Professor Hobart. Hobart's work on linical outcome measurements has directly influenced clinical research, trials and drug licensing, especially in MS and Alzheimer's disease. The MS scales developed by Hobart have been endorsed by the United States FDA and are in demand by commercial organisations in the development and trialling of treatments for MS and have led to the licensing of new drugs. Zajicek has led the topical field in evaluating the potential benefits and risks of cannabis for treating MS, contributing to the evidence base behind the medical use of cannabinoids in general, and pioneering its global potential use to slow neurodegeneration.
First commercialised in 1996, Quadrupole Orthogonal Acceleration Time of Flight (Q-TOF) Mass Spectrometry (MS) has become the most important of the enabling technologies for structural characterisation in `omics research including Proteomics, Metabolomics, Glycomics and Lipidomics. Prior to this revolutionary development, mass spectrometric methods lacked the sensitivity and resolution needed for unambiguous structural characterisation at the femtomole (10- 15M) level. Today, research is both enabled and accelerated by the use of many thousands of Q-TOF instruments in medical research, cancer research, pharmaceutical, biotechnology, forensics and chemical industry laboratories worldwide. As a consequence of this innovation, which resulted from the research and consultancy advice of Professor Howard Morris, industry has invested in R&D, and highly skilled (mainly British) jobs have been created as well as protected.
Research at the University of Aberdeen has directly contributed to the development of the cannabis-based medicine, Sativex®, which was licensed in the UK in 2010 for relieving neuropathic pain and spasticity of multiple sclerosis (MS), removing the need for patients to self-medicate with illegal, "unregulated" cannabis. The research has both enhanced patient welfare and promoted collaboration with industry. Several other countries have also approved Sativex®. Apart from such direct benefits, the research has also increased understanding of the benefits of cannabis-based medicines among the general public, and the main researcher has advised the Home Office on pertinent legislation. Therefore the claimed impact here includes benefits to health and welfare guidelines and on the public understanding of science. In addition industry has invested in research and development and a new product has been commercialised.
Nu Instruments is a successful mass spectrometer company set up in collaboration with geochemists at the University of Oxford. This joint effort was initially based around the development of a new kind of mass spectrometer; the Nu Plasma. Subsequent research in the UoA demonstrated the capabilities of this instrument for analysis of a large range of isotope systems, leading to its widespread use in geochemical and industrial laboratories around the world. Research in the UoA also aided in creation of new products, further contributing to growth in sales. Nu Instruments have sold over 150 instruments worldwide since 2008, while their turnover grew from £5.2M to £14.7M, and their employee numbers more than doubled to 105.
By identifying a novel approach to treat allergy and autoimmune disease the University of Bristol has created a new field of research into antigen-specific peptide immunotherapy. Initial work carried out by Professor David Wraith at the University has since 2008 led to the creation of new businesses, (including the spinout company Apitope), generated 100s of millions of pounds of investment and underpinned both the adoption of new technology and the development of new products by the pharmaceutical industry. The commercial impact of this research into antigen specific immunotherapy is on-going and expanding.
Carol Robinson's research at the University of Oxford in the mid-1990s led directly to her proposing a new type of mass spectrometer to enable more detailed analyses of larger molecular assemblies than previously possible. The design is marketed worldwide by Micromass UK Ltd (part of Waters Corporation), generating a new area of research within industry and academia in which intact protein complexes can be analysed by mass spectrometry and the chemistry of small molecules and drugs bound to them investigated, thus contributing to the search for novel pharmaceuticals. Since 2008, Waters' successful commercialisation of the new technology has led to sales worth many millions of dollars.
Researchers at the Dunn School of Pathology at the University of Oxford have played a major role in the development of an effective and innovative treatment for the chronic debilitating disease multiple sclerosis (MS). Research arising from the work of immunologists in Oxford, and partner neuroscientists in Cambridge University, has shown that low dose treatment with the lymphocyte depleting antibody alemtuzumab can break the cycle of disease in MS. Alemtuzumab acts by re-setting the immune system, leading to long-term arrest or remission, without increasing the risk of infection or malignancy. Large-scale studies since 2008 have shown that treatment is more effective and better tolerated than conventional forms of therapy. In June 2013, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the drug be licensed for people with active relapsing-remitting MS. The research by Oxford University and its collaborators into the use of alemtuzumab in MS has been shown to benefit patients; it offers hope to millions of sufferers worldwide; and has had a major impact on the pharmaceutical industry.